NRx Pharmaceuticals NRXPW Stock
NRx Pharmaceuticals Price Chart
NRx Pharmaceuticals NRXPW Financial and Trading Overview
| NRx Pharmaceuticals stock price | 0.0026 USD |
| Previous Close | 0 USD |
| Open | 0.16 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.0026 - 0.0033 USD |
| 52 Week Range | 0.0026 - 0.0033 USD |
| Volume | 176.26K USD |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.017 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.247 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NRXPW Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
NRx Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 2.017 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | 27.18% |
| 52 Week High | 0.0033 USD |
| 52 Week Low | 0.0026 USD |
| 50-Day Moving Average | N/A |
| 200-Day Moving Average | N/A |
NRXPW Share Statistics
| Avg. Volume (3 month) | N/A |
| Avg. Daily Volume (10-Days) | N/A |
| Shares Outstanding | N/A |
| Float | 30.45M |
| Short Ratio | N/A |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | N/A |
| Most Recent Quarter (mrq) | N/A |
| Next Fiscal Year End | N/A |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -444.56% |
| Gross Margin | 50.45% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -110.22% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 2.29M USD |
| Revenue Per Share (ttm) | 0.09 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.16M USD |
| EBITDA | -17057000 USD |
| Net Income Avi to Common (ttm) | -24540000 USD |
| Diluted EPS (ttm) | -6.247 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.71M USD |
| Total Cash Per Share (mrq) | 0.19 USD |
| Total Debt (mrq) | 934K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.292 |
| Book Value Per Share (mrq) | -0.413 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14927000 USD |
| Levered Free Cash Flow (ttm) | -8542125 USD |
Profile of NRx Pharmaceuticals
| Country | United States |
| State | DE |
| City | Wilmington |
| Address | 1201 N. Market Street |
| ZIP | 19801 |
| Phone | 484 254 6134 |
| Website | https://www.nrxpharma.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 29 |
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Q&A For NRx Pharmaceuticals Stock
What is a current NRXPW stock price?
NRx Pharmaceuticals NRXPW stock price today per share is 0.0026 USD.
How to purchase NRx Pharmaceuticals stock?
You can buy NRXPW shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NRx Pharmaceuticals?
The stock symbol or ticker of NRx Pharmaceuticals is NRXPW.
How many shares does NRx Pharmaceuticals have in circulation?
The max supply of NRx Pharmaceuticals shares is 0.
What is NRx Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
NRx Pharmaceuticals PE Ratio is now.
What was NRx Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
NRx Pharmaceuticals EPS is -6.247 USD over the trailing 12 months.